Figure 4.
Simon-Makuch plots for RFS according to WT1 MRD and postremission therapy (allo-SCT or no allo-SCT) in patients with intermediate-/unfavorable-risk AML. MRDhigh, patients with WT1/100ABL >2.5% in BM or >0.5% in PB. MRDlow, patients with WT1/100ABL <2.5% in BM or <0.5% in PB.

Simon-Makuch plots for RFS according to WT1 MRD and postremission therapy (allo-SCT or no allo-SCT) in patients with intermediate-/unfavorable-risk AML. MRDhigh, patients with WT1/100ABL >2.5% in BM or >0.5% in PB. MRDlow, patients with WT1/100ABL <2.5% in BM or <0.5% in PB.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal